MedImmune

MedImmune was founded in 1988 by Wayne T. Hockmeyer and Franklin Top, two visionary doctors from the Walter Reed Army Hospital in Washington, D.C. Their mission was to develop innovative solutions to combat and prevent infectious diseases, immune regulation issues, and cancer. The company quickly established itself as a leader in the biopharmaceutical industry, focusing on unmet medical needs.

A significant milestone in MedImmune's journey was its acquisition by AstraZeneca in 2007 for $15.6 billion. This acquisition marked a pivotal moment, allowing MedImmune to leverage AstraZeneca's global reach and resources to accelerate its research and development efforts. The acquisition also positioned MedImmune as AstraZeneca's global biologics research and development arm, enhancing its capabilities in developing cutting-edge biologics.

Throughout its history, MedImmune has been involved in several strategic acquisitions to bolster its research capabilities. Notable acquisitions include Amplimmune in 2013 for $500 million and Definiens in 2014 for $150 million. These acquisitions strengthened MedImmune's position in the immuno-oncology space, allowing it to expand its portfolio and enhance its expertise in developing novel therapies.

MedImmune's journey reflects a commitment to scientific innovation and strategic growth. By focusing on developing groundbreaking therapies and leveraging strategic partnerships, MedImmune has played a crucial role in advancing the field of biopharmaceuticals. Today, as part of AstraZeneca, MedImmune continues to push the boundaries of medical science, striving to improve patient outcomes worldwide.